Status:
COMPLETED
Effectiveness of Low Dose Aspirin in Decreasing the Chance Getting Stomach and Intestine Cancer
Lead Sponsor:
Bayer
Conditions:
Gastrointestinal Cancer
Eligibility:
All Genders
40+ years
Brief Summary
In this study, researchers wanted to learn more about the effect of Aspirin taken as low dose (75 - 300 mg) in preventing stomach, colorectal and esophagus cancer. The researchers were interested in t...
Eligibility Criteria
Inclusion
- \- Received prescription of either low-dose aspirin (75-300 mg) or paracetamol monotherapy during enrolment period.
Exclusion
- Received prescription of aspirin monotherapy or combination one year prior to the index date
- Recorded diagnoses of any type of cancer before the index date
- Recorded procedures of colectomy, gastrectomy prior to the index date
- Age \< 40 years
Key Trial Info
Start Date :
July 31 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 25 2020
Estimated Enrollment :
99999 Patients enrolled
Trial Details
Trial ID
NCT04081831
Start Date
July 31 2019
End Date
August 25 2020
Last Update
April 19 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Hong Kong
Hong Kong, Hong Kong